Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.

Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, Farzan N, Shiloach J, Bryla DA, Majadly F, Roberson R, Robbins JB, Schneerson R.

Infect Immun. 2001 Mar;69(3):1351-7.

2.

Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.

Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R; Israel Shigella Study Group.

Pediatr Infect Dis J. 2003 Aug;22(8):701-6.

PMID:
12913770
3.

Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.

Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, Robbins JB, Schneerson R.

J Infect Dis. 1999 Jun;179(6):1565-8.

PMID:
10228084
5.

O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative.

Chowers Y, Kirschner J, Keller N, Barshack I, Bar-Meir S, Ashkenazi S, Schneerson R, Robbins J, Passwell JH.

Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2396-401. Epub 2007 Feb 7. Erratum in: Proc Natl Acad Sci U S A. 2007 May 1;104(18):7729.

6.

Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.

Passwell JH, Ashkenzi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, Robbins JB, Schneerson R; Israeli Shigella Study Group.

Vaccine. 2010 Mar 2;28(10):2231-5. doi: 10.1016/j.vaccine.2009.12.050. Epub 2010 Jan 5.

PMID:
20056180
7.

Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice.

Pavliakova D, Chu C, Bystricky S, Tolson NW, Shiloach J, Kaufman JB, Bryla DA, Robbins JB, Schneerson R.

Infect Immun. 1999 Oct;67(10):5526-9.

8.
10.

Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.

Cohen D, Ashkenazi S, Green M, Lerman Y, Slepon R, Robin G, Orr N, Taylor DN, Sadoff JC, Chu C, Shiloach J, Schneerson R, Robbins JB.

Infect Immun. 1996 Oct;64(10):4074-7.

11.

Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.

Cohen D, Orr N, Robin G, Slepon R, Ashkenazi S, Ashkenazi I, Shemer J.

Clin Diagn Lab Immunol. 1996 Jul;3(4):451-5.

12.

Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.

Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, Yavzori M, Orr N, Block C, Ashkenazi I, Shemer J, Taylor DN, Hale TL, Sadoff JC, Pavliakova D, Schneerson R, Robbins JB.

Lancet. 1997 Jan 18;349(9046):155-9.

PMID:
9111538
13.

Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Konadu EY, Lin FY, Hó VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas AB, Li J, Bryla DA, Robbins JB, Szu SC.

Infect Immun. 2000 Mar;68(3):1529-34.

14.

Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates.

Robbins JB, Kubler-Kielb J, Vinogradov E, Mocca C, Pozsgay V, Shiloach J, Schneerson R.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7974-8. doi: 10.1073/pnas.0900891106. Epub 2009 Apr 3.

15.
16.

Shigella lipopolysaccharide antibodies in pediatric populations.

Passwell JH, Freier S, Shor R, Farzam N, Block C, Lison M, Shiff E, Ashkenazi S.

Pediatr Infect Dis J. 1995 Oct;14(10):859-65.

PMID:
8584312
17.
18.

Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, Bryla DA, Schneerson R, Robbins JB, Szu SC.

Infect Immun. 1999 Nov;67(11):5806-10.

19.

Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.

McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, Forbes E, Tian JH, Yang HH, Pace JL, Jackson WJ, Bourgeois AL.

Vaccine. 2006 May 1;24(18):3735-45. Epub 2005 Jul 21.

PMID:
16095766
20.

A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.

Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Bélot F, Cohen D, Sansonetti PJ, Mulard LA.

J Immunol. 2009 Feb 15;182(4):2241-7. doi: 10.4049/jimmunol.0803141.

Supplemental Content

Support Center